Monthly Archives: June 2015

Global Lithium Triflate Market Size, Share And Growth Report By 2015: Radiant Insights

RadiantInsights.com includes new market research report on “Global Lithium Triflate Market Size, Share And Trends Report To 2015 : Radiant Insights” to its huge collection of research reports.

2015 Global Lithium Triflate Industry Report is a professional and in-depth research report on the world’s major regional market conditions of the Lithium Triflate industry, focusing on the main regions (North America, Europe and Asia) and the main countries (United States, Germany, Japan and China).

The report firstly introduced the Lithium Triflate basics: definitions, classifications, applications and industry chain overview; industry policies and plans; product specifications; manufacturing processes; cost structures and so on. Then it analyzed the world’s main region market conditions, including the product price, profit, capacity, production, capacity utilization, supply, demand and industry growth rate etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Download sample Copy of This Report at:
http://www.radiantinsights.com/research/global-lithium-triflate-market-research-report-2015

The report includes six parts, dealing with:

1.) basic information;

2.) the Asia Lithium Triflate industry;

3.) the North American Lithium Triflate industry;

4.) the European Lithium Triflate industry;

5.) market entry and investment feasibility;

6.) the report conclusion.

Part I Lithium Triflate Industry Overview

Chapter One Lithium Triflate Industry Overview

1.1 Lithium Triflate Definition

1.2 Lithium Triflate Classification Analysis

1.2.1 Lithium Triflate Main Classification Analysis

1.2.2 Lithium Triflate Main Classification Share Analysis

1.3 Lithium Triflate Application Analysis

1.3.1 Lithium Triflate Main Application Analysis

1.3.2 Lithium Triflate Main Application Share Analysis

1.4 Lithium Triflate Industry Chain Structure Analysis

1.5 Lithium Triflate Industry Development Overview

1.5.1 Lithium Triflate Product History Development Overview

1.5.1 Lithium Triflate Product Market Development Overview

1.6 Lithium Triflate Global Market Comparison Analysis

1.6.1 Lithium Triflate Global Import Market Analysis

1.6.2 Lithium Triflate Global Export Market Analysis

1.6.3 Lithium Triflate Global Main Region Market Analysis

1.6.4 Lithium Triflate Global Market Comparison Analysis

1.6.5 Lithium Triflate Global Market Development Trend Analysis

See More Reports of This Category by Radiant Insights:
http://www.radiantinsights.com/catalog/chemicals

Chapter Two Lithium Triflate Up and Down Stream Industry Analysis

2.1 Upstream Raw Materials Analysis

2.1.1 Upstream Raw Materials Price Analysis

2.1.2 Upstream Raw Materials Market Analysis

2.1.3 Upstream Raw Materials Market Trend

2.2 Down Stream Market Analysis

2.1.1 Down Stream Market Analysis

2.2.2 Down Stream Demand Analysis

2.2.3 Down Stream Market Trend Analysis

Latest Report by Radiant Insights:

The 5G Wireless Ecosystem: 2015 – 2025 – Technologies, Applications, Verticals, Strategies & Forecasts:
http://www.radiantinsights.com/research/the-5g-wireless-ecosystem-2015-2025-technologies-applications-verticals-strategies-forecasts

The “5G Wireless Ecosystem: 2015 – 2025 – Technologies, Applications, Verticals, Strategies & Forecasts” report presents an in-depth assessment of the emerging 5G ecosystem including key market drivers, challenges, enabling technologies, use cases, vertical market applications, spectrum bands, wireless carrier deployment commitments and vendor strategies. The report also presents forecasts for both 5G investments and subscriptions.

The report comes with an associated Excel datasheet suite covering quantitative data from all numeric forecasts presented in the report.

About Radiant Insights

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

For more information, visit: http://www.radiantinsights.com/

Blog URL: http://www.terrapass.org/

Logo: http://www.abnewswire.com/pressreleases/wp-content/uploads/2015/06/1434349899.png

“Radiant Insights”

Media Contact
Company Name: Radiant Insights, Inc.
Contact Person: Michelle Thoras, Corporate Sales Specialist – USA
Email: sales@radiantinsights.com
Phone: (415) 349-0054, Toll Free: 1-888-202-9519
Address:28 2nd Street, Suite 3036
City: San Francisco
State: Califonia
Country: United States
Website: http://www.radiantinsights.com/research/global-lithium-triflate-market-research-report-2015

Source: ABNewswire

ReleaseID: 30524

Global Alopecia, Plague And Vasculitis Pipeline Market Review Up To 2015: Radiant Insights

RadiantInsights.com include new market research report “Alopecia, Plague And Vasculitis Pipeline Market Review Up To 2015” to its huge collection of research reports.

Alopecia – Pipeline Review, H1 2015

Global Markets Direct’s, ‘Alopecia – Pipeline Review, H1 2015’, provides an overview of the Alopecia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Alopecia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alopecia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

For more Information About Alopecia – Pipeline Review, H1 2015 Click:
http://www.radiantinsights.com/research/alopecia-pipeline-review-h1-2015

Plague – Pipeline Review, H1 2015

Global Markets Direct’s, ‘Plague – Pipeline Review, H1 2015’, provides an overview of the Plague’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Plague, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Plague and special features on late-stage and discontinued projects.

For more Information About Plague – Pipeline Review, H1 2015 Click:
http://www.radiantinsights.com/research/plague-pipeline-review-h1-2015

Vasculitis – Pipeline Review, H1 2015

Global Markets Direct’s, ‘Vasculitis – Pipeline Review, H1 2015’, provides an overview of the Vasculitis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Vasculitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vasculitis and special features on late-stage and discontinued projects.

For more Information About Vasculitis – Pipeline Review, H1 2015 Click:
http://www.radiantinsights.com/research/vasculitis-pipeline-review-h1-2015

About Radiant Insights

For more information, visit: http://www.radiantinsights.com/

Blog URL: http://www.terrapass.org/

Logo: http://www.abnewswire.com/pressreleases/wp-content/uploads/2015/06/1434348265.png

“Radiant Insights”

Source: ABNewswire

ReleaseID: 30522

INVESTOR NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Bio-Reference Laboratories, Inc. (BRLI) Over the Proposed Sale of the Company to OPKO HEALTH, INC. in a Stock Deal

Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Bio-Reference Laboratories, Inc.

NEW YORK, NY / ACCESSWIRE / June 15, 2015 / Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Bio-Reference Laboratories, Inc. (“Bio-Reference’ or the “Company”) (NasdaqGS: BRLI) for potential breaches of fiduciary duties in connection with the sale of the Company to OPKO HEALTH, INC. The Company’s stockholders will only receive 2.75 shares of OPKO common stock for each share of Bio-Reference common stock they own. Based on a closing price of $19.12 per share of OPKO common stock on June 3, 2015, the transaction is valued at approximately $52.58 per share of Bio-Reference common stock.

Bio-Reference shareholders will be subject to the future price fluctuation of OPKO’s stock price.

Click here for more information: www.faruqilaw.com/BRLI. There is no cost or obligation to you.

The investigation focuses on whether Bio-Reference’s Board of Directors breached their fiduciary duties to the Company’s stockholders by failing to conduct a fair sales process and whether and by how much this proposed transaction undervalues the Company to the detriment of Bio-Reference’s shareholders.

Faruqi & Faruqi, LLP is a national law firm which represents investors and individuals in class action litigation. The firm is focused on providing exemplary legal services in complex litigation in the areas of securities, shareholder, antitrust and consumer litigation, throughout all phases of litigation. The firm has an experienced trial team which has achieved significant victories on behalf of the firm’s clients. To keep track of the latest securities litigation news, follow us on Twitter at www.twitter.com/MergerActivity or on Facebook at www.facebook.com/FaruqiLaw.

If you own common stock in Bio-Reference and wish to obtain additional information and protect your investments free of charge, please visit us at www.faruqilaw.com/BRLI or contact Juan E. Monteverde, Esq. either via e-mail at jmonteverde@faruqilaw.com or by telephone at (877) 247-4292 or (212) 983-9330.

Contact:

Faruqi & Faruqi, LLP
369 Lexington Avenue, 10th Floor
New York, NY 10017
Attn: Juan E. Monteverde, Esq.
jmonteverde@faruqilaw.com
Toll Free: (877) 247-4292
Phone: (212) 983-9330

Attorney Advertising. (C) 2015 Faruqi & Faruqi, LLP. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We are happy to discuss your particular case.

SOURCE: Faruqi & Faruqi, LLP

ReleaseID: 429842

Zofran Lawyers Monheit Law Reports Ohio Parents Claim Zofran Caused Fatal Heart Defect

June 15, 2015 – – Zofran Laywers Monheit Law reports on June 10, 2015, a family from Ohio filed the most recent lawsuit against GlaxoSmithKline, manufacturer of the anti-nausea drug Zofran, report experienced birth defect attorneys at Monheit Law. This ongoing litigation, in which parents have claimed that Zofran, a common “off-label” treatment for morning sickness, caused their children to develop major birth defects, has now grown to at least 10 lawsuits.

This new complaint was filed in the US District Court for the Northern District of Ohio, Western Division, under case number 3:15-cv-1166. In court documents, which can be read here, a couple from Toledo alleges that their daughter was born with a severe congenital heart defect after being exposed to Zofran in utero. This abnormality would prove fatal, they claim, as their child passed away only three days after delivery.

The mother says that she was prescribed Zofran to relieve the symptoms of nausea and vomiting common during the first trimester. She states that her pregnancy was “unremarkable until nine days before delivery when the baby’s heart rate began to decelerate,” or slow abnormally. Her daughter was born on March 17, 2006, she claims, and quickly diagnosed with a “right ventrical heart defect.” After only three days, the child went into cardiac arrest and physicians were unable to revive her, plaintiff says. The child was pronounced dead on March 20, 2006.

Like previous plaintiffs, and the US federal government before them, this family alleges that GlaxoSmithKline promoted Zofran, a drug that is not approved for use during pregnancy, as a “safe and effective” morning sickness treatment. As these parents have noted, GlaxoSmithKline has never studied the effects of Zofran on pregnant women in clinical trials, a type of study that would be necessary for FDA approval of its use during pregnancy.

In 2012, the US Department of Justice charged GlaxoSmithKline for promoting Zofran to physicians as a remedy for morning sickness, in violation of federal law. While GlaxoSmithKline denies this allegation, every plaintiff in the Zofran litigation has maintained the accusation. But claimants go further, accusing the company of promoting Zofran for this “off-label” use even in the face of mounting evidence that the drug increases the risks for birth defects. Plaintiffs say that GlaxoSmithKline has concealed evidence indicating Zofran’s role in fetal harm from the US Food & Drug Administration, doctors and the public.

Plaintiffs note a series of recent epidemiological studies that have found an association between prenatal exposure to Zofran and significantly increased rates of birth defects, including heart defects like the one parents in this new case say proved fatal for their daughter. Claimants have also pointed to a wave of birth defect reports that they say GlaxoSmithKline has been receiving since at least 1992. Claimants allege that the company failed to report a significant amount of these reports to the FDA.

But the family from Ohio is notable for discussing the “Einarson study,” a study that other lawsuits have not mentioned. Completed in 2004, and funded by a grant from GlaxoSmithKline, this study compared the birth outcomes of 176 pregnant women who had taken Zofran to the birth outcomes of 176 women who had not. Plaintiffs write that “the study showed twice the rate of ‘Major malformation’ (3.5% as opposed to 1.8%)” among babies who were exposed to Zofran in utero. And while the article’s authors could not consider this increase “statistically significant” due to their study’s small sample size, plaintiffs claim that it was a “danger sign,” one that should have been investigated further. Plaintiffs accuse GlaxoSmithKline of failing to “commission a larger study,” and thus ignoring early evidence of Zofran’s potential link to major birth defects.

If these allegations are true, any parent who was prescribed Zofran during the first trimester and then delivered a child with birth defects may be able to bring a claim against GlaxoSmithKline. Led by attorney Michael Monheit, Esq., Monheit Law has gathered an alliance of experienced plaintiffs’ attorneys to investigate potential Zofran birth defect claims. The lawyers have been providing free consultations to parents and birth defect survivors who believe that prenatal exposure to Zofran may have caused them harm. For more information on the ongoing Zofran litigation and case eligibility, call 1-877-620-8411.

###

Contact ZofranLegal.com:

Michael Monheit
1-877-620-8411
michael@monheit.com
1368 Barrowdale Road, Rydal, PA 19046

ReleaseID: 60001973

Urgent Care Versus Emergency Care Article Reveals Informative Facts About Differences Between The Two Services

Urgent Care of Kona’s latest article takes on misconceptions about Urgent Care versus Emergency Care and sets the record straight with several useful facts to help Kona community residents and visitors to make more educated and informed decisions regarding differences between two different medical services.

Kailua-Kona, Hawaii, United States – June 15, 2015 /PressCable/ —

As part of their ongoing efforts to provide the best information on Urgent Care versus Emergency Care, Urgent Care of Kona has published a new article entitled, “Urgent Care Versus ER: What You Need To Know NOW” which sheds light on the most important aspects of Urgent Care versus Emergency Care for Kona community residents and visitors. Interested individuals can view the full article at http://m.urgentcareofkona.com/blog/post/urgent-care-versus-er-what-you-need-to-know-now.aspx

One of the most surprising pieces of information in the article is the fact that now more people seem to now truly understand the difference between Urgent Care services better as opposed to just Emergency Room services and the way that they can actually save money and time using Urgent Care services rather than the ER where waits are long and costly.

In discussing the article’s creation, Sanoe Fukui, Social Media Manager of Urgent Care of Kona said,

“This article was written to help consumers understand the difference and benefits that each medical service provides before the need arises. So as to help consumers make informed and more educated choices before actually needing these types of services.”

Kona community residents and visitors can find the most up-to-date version of the article at http://m.urgentcareofkona.com/blog/post/urgent-care-versus-er-what-you-need-to-know-now.aspx. Customers who have specific questions on past, present, or future articles contact Urgent Care of Kona via their website: www.urgentcareofkona.com

For more information about us, please visit http://www.urgentcareofkona.com

Contact Info:
Name: Dr. L
Email: konaurgentcaremanager@whmgmail.com
Organization: Urgent Care of Kona
Address: 77-311 Sunset Drive Kailua Kona Hawaii 96740
Phone: 1-808-327-4357

Release ID: 84482

Etelesolv Integrates with ServiceNow to Optimize IT Management for All Industries

Two Market-Leading IT Management Solutions Combined for Better Telecom Inventory Accuracy; Cimpl software functionalities enhance ServiceNow’s telecom inventory accuracy; Combined bidirectional communication with Cimpl improves ServiceNow workflows; Integrated business automation ensures seamless telecom inventory management

MONTREAL, QC / ACCESWIRE / June 15, 2015 / Etelesolv (www.etelesolv.com), Canada’s leader in IT and telecom expense management, is proud to announce it now integrates seamlessly with ServiceNow. The integration of Etelesolv’s Cimpl solution with ServiceNow’s service management software creates one of the most convenient and accurate centralized solutions for IT managers on the market.

Christopher Thierry, President of Etelesolv, had this to say, “Both Cimpl and ServiceNow are powerful productivity platforms for IT users across all industries. The integration between these systems offers a comprehensive solution that represents a new high-water mark for efficiently managing telecom and IT services under one umbrella. Cimpl’s integration with ServiceNow answers IT managers’ need for having the best market-leading telecom and IT service management tools in a single package.”

Etelesolv has integrated its Cimpl solution to work seamlessly with ServiceNow products. As a result, users of this combined service will experience huge accuracy gains in the already-efficient IT management workflows of ServiceNow. Cimpl augments ServiceNow by providing constant reconciliation and validation of invoices as well as enabling bi-directional communication between ServiceNow and many business platforms.

End users will experience the following benefits from jointly deploying Cimpl and ServiceNow:

– Enhanced IT inventory accuracy;
– Automated change management;
– More efficient workflows;
– Increased cost visibility, among many others.

More than ever, the efficiency of technology-enhanced processes and solutions drives success in business. The combination of Cimpl and ServiceNow is a timely integration of management solutions that will help IT managers in every industry optimize the deployment of telecom and IT services for their organizations.

About Etelesolv

With its global coverage, Etelesolv is leading a revolution in IT and Telecom Expense Management. Cimpl, Etelesolv’s signature platform, brings together actionable data analytics and automates everyday processes to ensure that companies know what they have and what their technology costs at any given time. Etelesolv’s business leadership and employee engagement have also earned serious acclaim. The company is recognized as a PROFIT 500 company because of its high revenue growth. Deloitte took note of Etelesolv’s technological innovation and cemented the company’s status as a technology heavyweight on its Technology Fast 50 and Fast 500 lists. Etelesolv is also ranked as a Best Small and Medium Employer (BSME) in Canada for 2013 and 2014. For more information, visit www.etelesolv.com.

Contact:

Caroline Le Brun
Marketing Manager
Etelesolv
514-949-4418
clebrun@etelesolv.com

SOURCE: Etelesolv

ReleaseID: 429803

Behavior Imaging Solutions Honored For Remote Autism Diagnostic Assessment Service

June 15, 2015 – – BOISE, Idaho (June 15, 2015): Boise-based Behavior Imaging Solutions announces they and 22 other companies from across the country are receiving the 2015 Tibbetts Award Today at the White House. The U.S. Small Business Administration (SBA) selected each small tech business for their exemplary roles in the Small Business Innovation Research (SBIR) program.

Behavior Imaging Solutions (BIS) was selected for its revolutionary ‘EHR-light’ video platforms and ‘Behavior Capture apps,’ enabling remote health and education assessments, improved clinical trial coordination and the foundation for the first-ever global remote autism diagnostic assessment service. The service is called NODA (Naturalistic Observation Diagnostic Assessment) and represents a development in collaboration with Phoenix-based Southwest Autism Research & Resource Center (SARRC) and Georgia Tech.

“The culmination of 12 years of research, NODA is now helping worried families get the answers they need and gain access to critical services sooner, at about half the cost of in-clinic testing,” said Ron Oberleitner, president and CEO of Behavior Imaging Solutions and father of a 22-year-old son with autism.

In the comfort of their homes, families use a smartphone app to capture video of their child’s behaviors in prescribed situations and upload the videos to a secure site. Expert SARRC clinicians evaluate the patient’s history, review videos, tag symptoms and typical and non-typical behaviors and render a diagnosis. A diagnostic report and guidance on next steps are issued to the family and can be reviewed with the child’s pediatrician. The process can be completed in two weeks or less.

The Tibbetts Award Ceremony features keynote speaker Cady Coleman, an accomplished scientist and NASA Astronaut noted for her six-month expedition to the International Space Station. Tibbetts Awardees will also be honored at the June 16 kickoff of the National SBIR/STTR Conference where thousands of the best and brightest in the innovation ecosystem convene annually.

“We’re thrilled with this recognition by the White House and national business leaders illustrating the value of technology innovations made possible by the SBIR funding program and their enormous impact on society through private markets and public/nonprofit/private-sector collaboration,” said Oberleitner.

Behavior Imaging Solutions is a division of Behavior Imaging?, founded in 2005 to invent and gain meaningful ad option for its technology as a means of increasing access to care remotely via digital health technology for individuals with special needs. Spurred by the son of company founders, Ron and Sharon Oberleitner, and his autism diagnosis in 1996, Behavior Imaging leveraged its leadership as a medical device company to help families and organizations improve accessibility to behavior and mental health diagnosis, treatment and research.

The company’s proprietary Behavior Imaging? platform was developed with the guidance of noted psychiatrists, behavior analysts and psychologists, specifically for the behavioral and mental health care industry. Video data captured from its patent-pending software apps on smartphones is an essential clinical tool, providing visual manifestation of many of the characteristics of disorders such as Autism, Traumatic Brain Injury (TBI), Post-Traumatic Stress Disorder (PTSD) and Alzheimer’s. More importantly, the observation and analysis of relevant behavior is often the only health treatment for these conditions. Similar to echocardiograms, CAT and MRI scans, and other traditional tools used for internal body imaging, Behavior Imaging? has the potential to become the standard imaging modality for treating behavioral and mental health conditions.

BIS is currently negotiating international licenses to accelerate adoption of its technology to create a worldwide footprint that provides global assistance to families. BIS also has been honored with the 2015 Google/Autism Speaks Pitch Playground Competition and as Idaho’s most Innovative Tech Company, 2008.

About Behavior Imaging Solutions

Behavior Imaging Solutions, a division of Behavior Imaging?, develops imaging and digital health solutions that lead to earlier diagnosis and better treatment options for a variety of behavioral health and special education applications. The company’s revolutionary ‘EHR-light’ video platforms enable remote health and education assessments, improved clinical trial coordination, and the NODA™ remote autism diagnostic assessment service. For more information, visit http://www.behaviorimaging.com.

About the SBA Tibbetts Award

Named for the late Roland Tibbetts, the annual Tibbetts Awards are presented to leaders from all over the United States who have been instrumental in supporting the success of the programs and/or utilizing SBIR/STTR investment to develop an ‘idea’ into a product or service that benefits the federal government’s research and development needs, the general public’s wellbeing, and the nation’s economy through technological innovation and the creation of high quality jobs – sometimes in newly created industries. Find out more about this year’s award ceremony here.

*Research described in this press release was supported by the National Institute of Mental Health of the National Institutes of Health under Award Number R44MH099035. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

###

Contact Behavior Imaging:

Denise D Resnik
602-956-8834 EXT 111
Denise@DRACommunications.com
1423 W. Franklin St. Boise, Idaho 83702 United States

ReleaseID: 60001972

Earth Enterprises Announces Free Trees And High Speed Digital Printing

June 15, 2015 – – The Greenest Printer in America is celebrating their 100th Anniversary; Earth Enterprise, the Leader in Environmental Printing, is announcing the availability of high quality, high speed, short run digital printing equipment in Mid-Town New York City, and a free tree planted in the buyers name for every new customer. Investing in these new capabilities adds increased support for their Catalog, Fashion, Real Estate Developer, and Book Publishing clients as well as many other vertical markets. Whether there’s a need to print coffee table books, financial filings, fashion pieces, Commercial or Residential Real Estate or other promotional materials, Earth Enterprise is a committed marketing support partner and NYC Printer.

Andy Hort, Chief Environmental Officer of Earth Enterprise, wants the NYC area to know that “Our ability to deliver fully customized pieces and incorporate multiple binding options reinforces our ability in customers minds to provide them with print materials that are tailored to individual recipients”. For a typical 8.5 x 11 book, quantities can range from a dozen, to hundreds, and still make better financial sense than running on typical offset equipment.

Depending on the readiness of artwork, binding requirements and ability to go to press quickly, jobs can be turned around rapidly, even in the same day. “We have been serving New York City and the Tri State Area for over 100 years. As a minority owned business, we are pleased to announce these cutting edge Digital printing capabilities. Our digital department is the only one in NYC that erases its own carbon footprint” says Susan Hort, Owner of Earth Enterprise.

Earth Enterprise uses only the most environmentally safe inks and papers, and they are committed to a carbon neutral impact for every job they print. They’ll even plant tree’s around the world to make sure they are giving back to the environment as part of that commitment. Using Indigo 3500 and 5600 equipment their machines can churn out 12”x18” or “13 x 19” — High Quality — 4 over 4 sheets at a rate of 800 per hour! This equipment also can produce Tradeshow Booth Printing, Banners, Posters, Wall Prints, Bus Enclosure’s and other Wide Format jobs at reasonable rates.

For 100 years, Earth Enterprise has been a trusted marketing partner, offering nyc printing services for high quality books, magazines and collateral materials and are located in Mid-Town New York City. They support clients with innovative design services, high-quality short and long-run print for promotional products. Earth Enterprise is one of the area’s largest printers who still has production and operations located in New York City; Providing Concept through In-House Marketing Services. They are also the nation’s leader in Environmental Printing efforts with a Carbon Offset plan that is unrivaled in North America.

###

Contact Earth Enterprise:

Andy Hort
642-362-3887
andy@earthenterprise.com
315 W 36TH STREET NEW YORK, NY 10018

ReleaseID: 60001967

Auphonix Product Range Set For A Shake-Up With New Products On The Horizon

June 15, 2015 – – Auphonix, inventor of a pop filter especially for the Blue Yeti microphone, announces that it will soon be expanding its product range to fulfil a whole range of unmet needs.

Owners of the Auphonix Pop Filter for the Blue Yeti are quick to praise the quality designs and low cost solutions to poor audio quality that this brand offers. In business now for almost two years, the company has achieved plenty of success, with rave reviews from both amateur and professional sound recording artists. These sophisticated pop filters have been featuring widely across the United States in commercial and private recording studios and demand continues to rise. Now Auphonix is pleased to announce that they will soon be adding to their exclusive range.

Lee Nolan, spokesman for Auphonix, hinted at what lies ahead for the company: “The last couple of years have been very exciting for us and now we want to explore new avenues. Our existing pop filters have proven to be highly efficient, versatile and durable. We’re really pleased with what we have been able to achieve. However, we know that there are plenty of other avenues to explore when it comes to enhancing microphone sound quality and creating new pop filters and other products for different set-ups. I think people involved in podcasting, gaming and webinars will be intrigued to see what we have planned for the next few months.”

While Mr. Nolan didn’t go into details about the new product range he did promise that it would meet customer expectations: “We have always prided ourselves in delivering top quality products, so you can be certain that any changes we make to our existing range or any new releases will have these values at the forefront. Cutting corners and selling inferior products is not what Auphonix stands for.”

Currently the Auphonix product range features on Amazon.com. It’s anticipated that any new product releases will also be conveniently available online. Anyone interested in improving audio quality will no doubt be looking forward to further news from Auphonix in the near future.

###

Contact Auphonix:

Lee Nolan
503-608-7667
lee@auphonix.com
9450 SW Gemini Dr #17337
Beaverton, OR 97008-7105

ReleaseID: 60001962

New Business WoofWoofRuff Bursts Onto The Market With Premium Quality Dog Toys

June 15, 2015 – – WoofWoofRuff is excited to announce the arrival of their inaugural range of affordable dog toys.

Recently established business WoofWoofRuff is aiming to entertain and indulge canine companions with a new range of colorful, exciting, and durable dog toys. A family owned and operated business, WoofWoofRuff was established out of the director’s love for dogs and difficulties finding quality toys that were affordable. This new exclusive range tailors to all personalities and is anticipated to be very popular.

In a recent interview with CEO and founder of WoofWoofRuff, Mr. Lee Nolan, he highlighted some of the advantages of their new product range: “In our personal experience we have found it hard to find dog toys that keep our pets entertained and are durable. Our dogs either lose interest, or the toy is chewed to bits within a couple of weeks. We are introducing a range of toy balls, chew toys, flying discs and toy ropes that will provide plenty of play and exercise for many hours. They are brightly colored so you won’t lose them easily at the park.”

WoofWoofRuff has developed toys for individual play and interactive play. The chew toys will keep dogs amused and help with gum and teeth health. The rope toys are designed for tug-of-war play, and flying discs and the balls can keep dogs running for hours. The balls are small enough to comfortably hold and throw, while the discs will neatly fold up for easy transport. Not only are these toys designed for fun, they also provide plenty of exercise and help to keep dogs fit and in shape.

The WoofWoofRuff toy range comes in combination packs of either two or three. This allows dog owners to mix and match depending on their pet’s personality. These products are currently featuring on Amazon.com and have been discounted to celebrate the official launch. Easily purchased online and shipped throughout the United States, WoofWoofRuff is confident that these new toys are going be a great value for both dogs and their owners.

###

Contact WoofWoofRuff:

Lee Nolan
+64273334240
lee@woofwoofruff.com
9450 SW Gemini Dr #17337
Beaverton, OR 97008-7105

ReleaseID: 60001960